| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
98.16(B) |
| Last
Volume: |
1,066,779 |
Avg
Vol: |
770,880 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,708 |
84,942 |
120,351 |
283,828 |
| Total Sell Value |
$38,834,511 |
$77,255,398 |
$106,848,389 |
$220,981,114 |
| Total People Sold |
9 |
13 |
15 |
17 |
| Total Sell Transactions |
20 |
38 |
53 |
116 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ryan Arthur F |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
19,347 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-01-03 |
4 |
AS |
$721.48 |
$72,629 |
D/D |
(100) |
19,182 |
|
3% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
2,434 |
|
- |
|
| Poon Christine A |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
2,037 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
1,247 |
|
- |
|
| Coles N Anthony |
Director |
– • – |
2022-12-28 |
4 |
AS |
$707.87 |
$4,111,822 |
D/D |
(5,758) |
1,093 |
|
6% |
|
| Coles N Anthony |
Director |
– • – |
2022-12-28 |
4 |
OE |
$374.12 |
$2,546,410 |
D/D |
5,758 |
6,851 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2022-12-20 |
4 |
D |
$728.86 |
$102,864 |
I/I |
(141) |
1,961 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,798 |
33,884 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,129 |
60,747 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,853 |
32,844 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,101 |
53,100 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,651 |
324,083 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,973 |
22,079 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,752 |
23,110 |
|
- |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,926 |
18,581 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-12-12 |
4 |
AS |
$730.17 |
$192,765 |
D/D |
(264) |
19,106 |
|
7% |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$186,060 |
D/D |
(247) |
16,655 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$370,614 |
D/D |
(492) |
30,086 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2022-12-09 |
4 |
D |
$753.28 |
$42,937 |
D/D |
(57) |
322,432 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$351,028 |
D/D |
(466) |
51,999 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$206,399 |
D/D |
(274) |
19,370 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$370,614 |
D/D |
(492) |
20,358 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$370,614 |
D/D |
(492) |
56,618 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$370,614 |
D/D |
(492) |
28,991 |
|
- |
|
2402 Records found
|
|
Page 10 of 97 |
|
|
34.13 (3.78%) 
